Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

Abstract EN

Background.

Emerging evidences have shown that long noncoding RNA SPRY4-IT1 can be aberrantly expressed in human cancers, and it could be an unfavorable prognostic factor in cancer patients.

However, the prognostic mechanism of SPRY4-IT1 is still unclear.

This study is aimed at evaluating its potential predictive value for cancer prognosis.

Methods.

We thoroughly searched PubMed, Embase, Web of Science, and MEDLINE databases so as to explore the relationship between SPRY4-IT1 expression and cancer prognosis value.

Then, TCGA datasets were used to validate the results of our meta-analysis.

Results.

In all, seventeen studies involving 1650 patients were included in this meta-analysis.

Pooled results showed that high expression of SPRY4-IT1 was significantly correlated with poor OS (HR=1.96, 95% confidence interval CI=1.47‐2.62, P<0.001) in cancer patients.

Furthermore, exploration of TCGA dataset further validated that SPRY4-IT1 was aberrantly expressed in various cancers, which partially confirmed our results in this meta-analysis.

Conclusions.

The present systematic review and meta-analysis implicated that the aberrant expressions of lncRNA SPRY4-IT1 were strongly associated with clinical survival outcomes in various cancers and therefore might serve as a promising biomarker for predicting prognosis of human cancers.